ETGLX: Eventide Gilead N

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

ETGLX Eventide Gilead N

  • Fund
  • ETGLX
  • Price as of: Oct 16, 2019
  • $38.87 - $0.54 - 1.37%
  • Primary Category
  • Uncategorized

ETGLX - Profile

Vitals

  • YTD Return 22.7%
  • 3 Yr Annualized Return 16.4%
  • 5 Yr Annualized Return 10.8%
  • Net Assets $2.37 B
  • Holdings in Top 10 34.1%

52 WEEK LOW AND HIGH

$38.87
$29.36
$42.61

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.39%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 38.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000

IRA

$1,000

Fund Classification

PRIMARY CATEGORY

Uncategorized
  • Fund Type Open End Mutual Fund
  • Investment Style Mid-Cap Growth

Distributions

  • YTD Total Return 22.7%
  • 3 Yr Annualized Total Return 16.4%
  • 5 Yr Annualized Total Return 11.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.37%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Eventide Gilead Fund
  • Fund Family Name Eventide Funds
  • Inception Date Jul 08, 2008
  • Shares Outstanding N/A
  • Share Class N
  • Currency USD
  • Domiciled Country United States
  • Manager Finny Kuruvilla

ETGLX - Performance

Return Ranking - Trailing

Period ETGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 22.7% -40.1% 50.7% 10.18%
1 Yr 3.9% -55.1% 47.0% 16.64%
3 Yr 16.4%* -33.7% 34.4% 7.42%
5 Yr 10.8%* -31.2% 24.2% 8.27%
10 Yr 13.8%* -13.8% 30.2% 10.19%

* Annualized


Return Ranking - Calendar

Period ETGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.5% -100.0% 23.6% 26.96%
2017 32.9% -55.3% 69.8% 6.34%
2016 0.9% -56.6% 80.1% 75.78%
2015 -3.3% -50.8% 22.5% 29.16%
2014 17.7% -87.7% 249.9% 5.80%

Total Return Ranking - Trailing

Period ETGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 22.7% -40.1% 50.7% 10.18%
1 Yr 3.9% -55.1% 47.0% 20.70%
3 Yr 16.4%* -34.6% 34.4% 8.04%
5 Yr 11.1%* -31.7% 24.2% 9.51%
10 Yr 14.0%* -13.8% 30.2% 10.47%

* Annualized


Total Return Ranking - Calendar

Period ETGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.5% -100.0% 23.6% 38.84%
2017 32.9% -55.3% 69.8% 7.42%
2016 0.9% -56.6% 80.1% 83.53%
2015 -2.1% -50.8% 30.8% 39.18%
2014 17.9% -87.7% 249.9% 6.38%

NAV & Total Return History

ETGLX - Holdings

Concentration Analysis

ETGLX Category Low Category High ETGLX % Rank
Net Assets 2.37 B 479 K 99.8 B 18.31%
Number of Holdings 64 1 6176 55.99%
Net Assets in Top 10 905 M -664 M 26.3 B 16.21%
Weighting of Top 10 34.14% 0.0% 20474.3% 46.32%

Top 10 Holdings

  1. Ascendis Pharma A/S ADR 4.88%

  2. Twilio Inc A 4.25%

  3. The Trade Desk Inc A 4.13%

  4. Sarepta Therapeutics Inc 3.72%

  5. Zogenix Inc 3.29%

  6. Sage Therapeutics Inc 2.97%

  7. Roper Technologies Inc 2.96%

  8. Waste Connections Inc 2.90%

  9. Wayfair Inc Class A 2.83%

  10. Palo Alto Networks Inc 2.21%


Asset Allocation

Weighting Return Low Return High ETGLX % Rank
Stocks
84.89% -45.78% 100.29% 36.65%
Cash
13.72% -6.52% 7388.76% 54.22%
Other
1.39% -7288.76% 38.16% 11.58%
Preferred Stocks
0.00% -0.89% 19.87% 56.54%
Convertible Bonds
0.00% -0.23% 16.29% 51.36%
Bonds
0.00% -106.39% 42.16% 62.26%

Stock Sector Breakdown

Weighting Return Low Return High ETGLX % Rank
Technology
27.91% -54.35% 73.59% 9.29%
Healthcare
26.02% -26.86% 79.31% 1.53%
Industrials
13.41% -21.11% 58.12% 12.90%
Consumer Cyclical
9.30% -18.86% 241.63% 42.16%
Utilities
2.81% -18.94% 75.11% 20.25%
Real Estate
2.47% -31.66% 60.83% 34.81%
Basic Materials
2.44% -78.19% 71.11% 43.41%
Consumer Defense
0.53% -78.39% 53.36% 74.76%
Financial Services
0.00% -3.49% 71.54% 92.65%
Energy
0.00% -7.00% 96.18% 82.80%
Communication Services
0.00% -95.92% 42.32% 82.94%

Stock Geographic Breakdown

Weighting Return Low Return High ETGLX % Rank
US
77.16% -24.97% 83.15% 26.16%
Non US
7.73% -64.08% 100.29% 50.68%

ETGLX - Expenses

Operational Fees

ETGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.39% 0.04% 27.58% 60.73%
Management Fee 1.00% 0.00% 2.94% 67.57%
12b-1 Fee 0.20% 0.00% 1.00% 22.38%
Administrative Fee 0.10% 0.01% 1.12% 65.64%

Sales Fees

ETGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.50% N/A

Trading Fees

ETGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.50% 2.00% N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

ETGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 38.00% 0.00% 5191.00% 41.76%

ETGLX - Distributions

Dividend Yield Analysis

ETGLX Category Low Category High ETGLX % Rank
Dividend Yield 0.00% 0.00% 14.33% 68.94%

Dividend Distribution Analysis

ETGLX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Monthly Annually

Dividend Payout History


Net Income Ratio Analysis

ETGLX Category Low Category High ETGLX % Rank
Net Income Ratio -0.37% -8.87% 4.47% 73.91%

Capital Gain Distribution Analysis

ETGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

ETGLX - Managers

Finny Kuruvilla

Manager

Start Date

Tenure

Tenure Rank

Jul 08, 2008

11.24

11.2%

Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.


Tenure Analysis

Category Low

0.0

Category High

35.78

Category Average

7.82

Category Mode

6.0